How to Buy Gufic Biosciences Ltd Shares?
You can easily buy the stocks/shares of Gufic Biosciences Ltd (GUFICBIO) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Gufic Biosciences Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of GUFICBIO as on 15th May 2025 is ₹388.86What is the return on Gufic Biosciences Ltd share?
The past returns of Gufic Biosciences Ltd (GUFICBIO) share are- Past 1 week: N/A
- Past 1 month: -90.17
- Past 3 months: 13.38
- Past 6 months: -14.12
- Past 1 year: 1.20
- Past 3 years: 71.88
- Past 5 years: 467.18
What is the Dividend yield % on Gufic Biosciences Ltd share?
The current dividend yield of Gufic Biosciences Ltd (GUFICBIO) is 0.03What is the Market Cap of Gufic Biosciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gufic Biosciences Ltd (GUFICBIO) is ₹3711.88Cr as of 15th May 2025What is the 52 Week High and Low of Gufic Biosciences Ltd?
The 52-week high and low of Gufic Biosciences Ltd (GUFICBIO) is ₹504.25 and ₹298.80.What is the PE and PB ratio of Gufic Biosciences Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Gufic Biosciences Ltd are 53.29 and 6.97 respectively.Which sector does Gufic Biosciences Ltd belong to?
Gufic Biosciences Ltd (GUFICBIO) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to Gufic Biosciences Ltd?
The peers or stocks similar to Gufic Biosciences Ltd are: and many others.Can't decide whether or not to buy Gufic Biosciences Ltd?
Worry no more! Login to Tickertape and check out Gufic Biosciences Ltd (GUFICBIO) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Gufic Biosciences Ltd?
The 52-week high and low of Gufic Biosciences Ltd (GUFICBIO) is ₹504.25 and ₹298.80.1. Test Stocks FAQ for Gufic Biosciences Ltd Shares?
You can easily buy the stocks/shares of Gufic Biosciences Ltd (GUFICBIO) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Gufic Biosciences Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of GUFICBIO as on 15th May 2025 is ₹388.86
Gufic Biosciences Ltd
GUFICBIO Share Price
388.863.04% (+11.46)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
GUFICBIO Performance & Key Metrics
GUFICBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 53.30 | 6.97 | 0.03% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
GUFICBIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GUFICBIO Company Profile
Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.55%
2.55%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
—
—
GUFICBIO Sentiment Analysis
GUFICBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
GUFICBIO Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
GUFICBIO Stock Growth Drivers
GUFICBIO Stock Growth Drivers
0
Hmm, looks like there are nogrowth drivers
GUFICBIO Stock Challenges
GUFICBIO Stock Challenges
1Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
GUFICBIO Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
GUFICBIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GUFICBIO
GUFICBIO
Income
Balance Sheet
Cash Flow
Annual Normal View
GUFICBIO Income Statement
GUFICBIO Income Statement
Annual Normal View
| Financial Year | FY 2024 | FY 2025 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 808.85 | 823.43 | 823.43 | |||
Raw Materials | 389.32 | 685.11 | 685.11 | |||
| Power & Fuel Cost | 17.79 | |||||
| Employee Cost | 109.63 | |||||
| Selling & Administrative Expenses | 103.90 | |||||
| Operating & Other expenses | 40.15 | |||||
EBITDA | 148.06 | 138.32 | 138.32 | |||
| Depreciation/Amortization | 17.02 | 21.06 | 21.07 | |||
| PBIT | 131.04 | 117.26 | 117.25 | |||
| Interest & Other Items | 15.36 | 23.11 | 23.11 | |||
| PBT | 115.68 | 94.15 | 94.14 | |||
| Taxes & Other Items | 29.54 | 24.49 | 24.50 | |||
| Net Income | 86.14 | 69.66 | 69.64 | |||
| EPS | 8.59 | 6.95 | 6.94 | |||
| DPS | 0.10 | 0.10 | 0.10 | |||
| Payout ratio | 0.01 | 0.01 | 0.01 |
GUFICBIO Company Updates
FY 2025FY 2025
Investor Presentation
May 30PDF
Nov 14PDF
GUFICBIO Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
GUFICBIO Past Performance & Peer Comparison
GUFICBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gufic Biosciences Ltd | 53.29 | 6.97 | 0.03% |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
GUFICBIO Stock Price Comparison
Compare GUFICBIO with any stock or ETFCompare GUFICBIO with any stock or ETF
GUFICBIO
GUFICBIO Holdings
GUFICBIO Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
GUFICBIO Promoter Holdings Trend
GUFICBIO Promoter Holdings Trend
GUFICBIO Institutional Holdings Trend
GUFICBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GUFICBIO Shareholding Pattern
GUFICBIO Shareholding Pattern
GUFICBIO Shareholding History
GUFICBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in GUFICBIO
Mutual Funds Invested in GUFICBIO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Gufic Biosciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.3715% | Percentage of the fund’s portfolio invested in the stock 1.79% | Change in the portfolio weight of the stock over the last 3 months -0.36% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/41 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9258% | Percentage of the fund’s portfolio invested in the stock 0.93% | Change in the portfolio weight of the stock over the last 3 months 0.93% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/32 (-21) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4283% | Percentage of the fund’s portfolio invested in the stock 0.21% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 111/131 (-15) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing GUFICBIO stock
smallcases containing GUFICBIO stock
Looks like this stock is not in any smallcase yet.
GUFICBIO Events
GUFICBIO Events
GUFICBIO Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
GUFICBIO Dividend Trend
No dividend trend available
GUFICBIO Upcoming Dividends
GUFICBIO Upcoming Dividends
No upcoming dividends are available
GUFICBIO Past Dividends
GUFICBIO Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 20, 2023
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 20, 2023
Cash Dividend
Ex DateEx DateAug 24, 2022
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Aug 24, 2022
Cash Dividend
Ex DateEx DateSep 9, 2021
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 9, 2021
Cash Dividend
Ex DateEx DateNov 3, 2020
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Nov 3, 2020
GUFICBIO Stock News & Opinions
GUFICBIO Stock News & Opinions
Articles & Videos
Earnings
Gufic BioSciences consolidated net profit declines 61.50% in the March 2025 quarter
Net profit of Gufic BioSciences declined 61.50% to Rs 7.72 crore in the quarter ended March 2025 as against Rs 20.05 crore during the previous quarter ended March 2024. Sales rose 5.14% to Rs 205.02 crore in the quarter ended March 2025 as against Rs 194.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 19.14% to Rs 69.65 crore in the year ended March 2025 as against Rs 86.14 crore during the previous year ended March 2024. Sales rose 1.63% to Rs 819.81 crore in the year ended March 2025 as against Rs 806.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales205.02194.99 5 819.81806.67 2 OPM %12.8717.55 -16.4318.08 - PBDT18.3731.46 -42 115.21132.69 -13 PBT10.5227.12 -61 94.14115.67 -19 NP7.7220.05 -61 69.6586.14 -19 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Gufic BioSciences standalone net profit declines 60.25% in the March 2025 quarter
Net profit of Gufic BioSciences declined 60.25% to Rs 7.97 crore in the quarter ended March 2025 as against Rs 20.05 crore during the previous quarter ended March 2024. Sales rose 5.14% to Rs 205.02 crore in the quarter ended March 2025 as against Rs 194.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 18.82% to Rs 69.93 crore in the year ended March 2025 as against Rs 86.14 crore during the previous year ended March 2024. Sales rose 1.63% to Rs 819.81 crore in the year ended March 2025 as against Rs 806.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales205.02194.99 5 819.81806.67 2 OPM %12.9917.55 -16.4618.08 - PBDT18.6131.46 -41 115.48132.70 -13 PBT10.7727.12 -60 94.42115.68 -18 NP7.9720.05 -60 69.9386.14 -19 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Gufic BioSciences recommends final dividend
Gufic BioSciences announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Gufic BioSciences to announce Quarterly Result
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Gufic BioSciences standalone net profit declines 13.21% in the December 2024 quarter
Net profit of Gufic BioSciences declined 13.21% to Rs 19.32 crore in the quarter ended December 2024 as against Rs 22.26 crore during the previous quarter ended December 2023. Sales rose 2.98% to Rs 207.79 crore in the quarter ended December 2024 as against Rs 201.78 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales207.79201.78 3 OPM %16.3418.07 - PBDT30.9033.70 -8 PBT26.2829.56 -11 NP19.3222.26 -13 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Gufic BioSciences to announce Quarterly Result
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Gufic Biosciences tumbles after Q2 PAT drops 6% YoY to Rs 22 cr
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review. EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24. Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Gufic Biosciences Q2 PAT drops 6% YoY to Rs 22 cr
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review. EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24. Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant. The scrip rose 1.95% o settle at Rs 446.65 on Thursday, 14 November 2024, the domestic stock market to remain closed today on account of Guru Nanak Jayanti.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Gufic BioSciences standalone net profit declines 6.16% in the September 2024 quarter
Net profit of Gufic BioSciences declined 6.16% to Rs 21.78 crore in the quarter ended September 2024 as against Rs 23.21 crore during the previous quarter ended September 2023. Sales declined 4.98% to Rs 204.18 crore in the quarter ended September 2024 as against Rs 214.87 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales204.18214.87 -5 OPM %18.9218.32 - PBDT33.5735.24 -5 PBT29.2730.94 -5 NP21.7823.21 -6 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Gufic BioSciences to discuss results
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant